SEOUL, South Korea--(BUSINESS WIRE)--ImmuneOncia (CEO Heung Tae Kim) announced the results of its Phase 1a solid tumour clinical trial (IMC-002-K102 Study) of IMC-002, a CD47 monoclonal antibody, at ...
Researchers from University of Kentucky report that antisense inhibition of CD47 improved glucose homeostasis, insulin ...
A new research paper was published in Volume 17, Issue 12 of Aging-US on December 1, 2025, titled “CD47 antisense ...
A new study has discovered a molecular signal that tumors exploit to exhaust the T cells meant to destroy them-and how silencing that signal could revive the body's immunity. The study led by Weill ...
CD47-null femoral fractures show reduced bone formation, but increased tissue mineral density. µCT analysis of transverse femoral fracture in WT (n = 9) and CD47-null (n = 11-14) mice at 10- and ...
A characteristic of tumors includes the ability to avoid the immune system. In many cases tumors can progress without detection of immune cells. In the literature many scientists refer to undetectable ...
Liminatus Pharma is a preclinical oncology company focused on a CD47 antibody, with no clinical pipeline and years away from human trials. CD47-targeting drugs have a track record of failure, making ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback